2Berry JM, Palefsky JM. A review of human papillomavirus vaccines:from basic science to clinical trials. Front Biosci, 2003, 8:333-345.
3Syrjanen S, Puranen M. Human papillomavirus infections in children:the potential role of maternal transmission.Crit Rev Oral Biol Med,2000,11 (2):259-274.
4Gudmundsdottir T, Tryggvadottir L, Allende M, et al. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. Aeta Obstet Gynecol Scand, 2003, 82(4):345-350.
5Breitburd F,Coursaget P. Human papillomavirus vaccines. Cancer biology, 1999,9:431-445.
6Borysiewicz LK, Fiander A, Nimako M, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 1996, 347:1523-1527.
7Bermudez-Humaran LG, Langella P, Miyoshi A, et al. Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. Appl Environ Microbiol. 2002.68(2):917-922.
8Zwaveling S, Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol, 2002,169( 1 ):350-358.
9Liu DW, Tsao YP, Kung JT, et al. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer. J Virol, 2000,74(6):2888-2894.
10Wolkers MC, Toebes M, Okabe M, et al. Optimizing the efficacy of epitope-directed DNA vaccination. J Immunol, 2002,168(10):4998-5004.
